Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
7.00
+0.27 (4.01%)
May 20, 2025, 4:00 PM - Market closed
Atara Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 13.84 | 25.03 | 25.84 | 92.94 | 106.08 | 200.4 | Upgrade
|
| Short-Term Investments | - | 17.47 | 25.88 | 149.88 | 264.98 | 300.26 | Upgrade
|
| Cash & Short-Term Investments | 13.84 | 42.5 | 51.73 | 242.82 | 371.07 | 500.66 | Upgrade
|
| Cash Growth | -70.07% | -17.84% | -78.70% | -34.56% | -25.88% | 93.22% | Upgrade
|
| Accounts Receivable | 8.88 | 1.48 | 34.11 | 40.22 | 0.99 | - | Upgrade
|
| Other Receivables | - | - | - | 0.8 | 0.8 | 1.95 | Upgrade
|
| Receivables | 8.88 | 1.48 | 34.11 | 41.02 | 1.79 | 1.95 | Upgrade
|
| Inventory | - | 10.66 | 9.71 | 1.59 | - | - | Upgrade
|
| Prepaid Expenses | - | - | - | - | - | 20.47 | Upgrade
|
| Restricted Cash | 0.15 | 0.15 | 0.15 | 0.15 | 0.19 | 0.19 | Upgrade
|
| Other Current Assets | 4.32 | 10.12 | 6.18 | 9.51 | 11.57 | - | Upgrade
|
| Total Current Assets | 27.18 | 64.89 | 101.87 | 295.08 | 384.62 | 523.27 | Upgrade
|
| Property, Plant & Equipment | 32.01 | 41.1 | 58.79 | 74.32 | 79.94 | 62.82 | Upgrade
|
| Other Long-Term Assets | 2.84 | 3.1 | 4.84 | 7.02 | 3.57 | 2.03 | Upgrade
|
| Total Assets | 62.04 | 109.1 | 165.5 | 376.42 | 468.13 | 588.12 | Upgrade
|
| Accounts Payable | 1.38 | 4.37 | 3.68 | 6.87 | 17.37 | 7.12 | Upgrade
|
| Accrued Expenses | 6.38 | 21.2 | 48.53 | 50.41 | 44.91 | 40.34 | Upgrade
|
| Current Portion of Leases | - | 13.92 | 12.18 | 13.64 | 2.75 | 1.99 | Upgrade
|
| Current Unearned Revenue | 15.98 | 95.09 | 77.83 | 8 | 40.76 | 33.46 | Upgrade
|
| Total Current Liabilities | 47.89 | 134.57 | 142.23 | 78.92 | 105.79 | 82.9 | Upgrade
|
| Long-Term Leases | 26.71 | 31.52 | 45.69 | 58.06 | 25.52 | 13.04 | Upgrade
|
| Long-Term Unearned Revenue | 39.38 | 38.62 | 72.19 | 107.24 | 55.71 | 27.8 | Upgrade
|
| Other Long-Term Liabilities | 3.13 | 1.67 | 4.63 | 5.56 | 1.5 | 2.04 | Upgrade
|
| Total Liabilities | 117.11 | 206.38 | 264.74 | 249.78 | 188.51 | 125.78 | Upgrade
|
| Common Stock | 0 | 0 | - | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 1,961 | 1,957 | 1,870 | 1,822 | 1,745 | 1,587 | Upgrade
|
| Retained Earnings | -2,017 | -2,055 | -1,969 | -1,693 | -1,465 | -1,125 | Upgrade
|
| Comprehensive Income & Other | - | 0.01 | -0.2 | -2.07 | -0.37 | 0.3 | Upgrade
|
| Shareholders' Equity | -55.07 | -97.28 | -99.23 | 126.64 | 279.61 | 462.34 | Upgrade
|
| Total Liabilities & Equity | 62.04 | 109.1 | 165.5 | 376.42 | 468.13 | 588.12 | Upgrade
|
| Total Debt | 26.71 | 45.43 | 57.87 | 71.7 | 28.27 | 15.03 | Upgrade
|
| Net Cash (Debt) | -12.87 | -2.94 | -6.15 | 171.12 | 342.8 | 485.63 | Upgrade
|
| Net Cash Growth | - | - | - | -50.08% | -29.41% | 99.53% | Upgrade
|
| Net Cash Per Share | -1.47 | -0.39 | -1.45 | 41.94 | 91.49 | 164.13 | Upgrade
|
| Filing Date Shares Outstanding | 5.96 | 5.86 | 4.77 | 3.84 | 3.72 | 3.34 | Upgrade
|
| Total Common Shares Outstanding | 5.92 | 5.86 | 4.26 | 3.84 | 3.67 | 3.33 | Upgrade
|
| Working Capital | -20.71 | -69.68 | -40.36 | 216.16 | 278.84 | 440.37 | Upgrade
|
| Book Value Per Share | -9.30 | -16.60 | -23.31 | 33.00 | 76.25 | 138.64 | Upgrade
|
| Tangible Book Value | -55.07 | -97.28 | -99.23 | 126.64 | 279.61 | 462.34 | Upgrade
|
| Tangible Book Value Per Share | -9.30 | -16.60 | -23.31 | 33.00 | 76.25 | 138.64 | Upgrade
|
| Machinery | - | 17.67 | 18.66 | 17.82 | 26.05 | 19.18 | Upgrade
|
| Construction In Progress | - | - | 0.16 | 0.03 | 6.33 | 0.88 | Upgrade
|
| Leasehold Improvements | - | 0.93 | 0.9 | 0.88 | 50.14 | 50.13 | Upgrade
|
Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.